Autolus Therapeutics plc (AUTL)
NMS · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 20.9M | 21.2M | 24.3M | 26.2M |
| Gross Profit | -3.5M | -7.4M | -1.0M | 1.6M |
| Operating Income | -61.2M | -71.6M | -72.5M | -59.5M |
| Net Income | -47.9M | -79.1M | -90.3M | -71.6M |
| Diluted EPS | $-0.18 | $-0.30 | $nan | $-0.27 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 6.2M | 1.7M | 10.1M | 75.4M |
| Gross Profit | 1.7M | -1.3M | -21.0M | |
| Operating Income | -142.9M | -175.5M | -241.4M | -270.5M |
| Net Income | -148.8M | -208.4M | -220.7M | -287.5M |
| Diluted EPS | $-1.57 | $-1.20 | $-0.86 | $-1.08 |